Rilzabrutinib
( DrugBank: Rilzabrutinib / KEGG DRUG: Rilzabrutinib )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 35 | Pemphigus | 5 |
| 61 | Autoimmune hemolytic anemia | 9 |
| 63 | Idiopathic thrombocytopenic purpura | 17 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
| 223 | Primary membranoproliferative glomerulonephritis | 1 |
| 300 | IgG4-related disease | 5 |
35. Pemphigus
Clinical trials : 130 / Drugs : 159 - (DrugBank : 46) / Drug target genes : 28 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
61. Autoimmune hemolytic anemia
Clinical trials : 218 / Drugs : 186 - (DrugBank : 42) / Drug target genes : 27 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
223. Primary membranoproliferative glomerulonephritis
Clinical trials : 243 / Drugs : 296 - (DrugBank : 84) / Drug target genes : 46 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
300. IgG4-related disease
Clinical trials : 81 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 152
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|